[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340228-105":59,"doc-detail-340228-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","therapeutic-advances-in-vaccines-and-immunotherapy-review-2024-vol-12","TherapeuTic advances in vaccines and immunotherapy - Review - 2024 Vol. 12","","Multiple myeloma (MM) is a bone marrow cancer and a major hematological malignancy, yet its immunotherapy outcomes have lagged despite rapid progress in other cancer fields. Clinical studies of immune checkpoint inhibitors, alone or combined with anticancer drugs, show limited efficacy and increased adverse effects, especially in advanced MM. This review analyzes how exhaustion marker–related mechanisms shape the MM tumor microenvironment and discusses five inhibitory checkpoint pathways and emerging bispecific antibodies, supported by recent clinical trial evidence.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/therapeutic-advances-in-vaccines-and-immunotherapy-review-2024-vol-12/340228/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/therapeutic-advances-in-vaccines-and-immunotherapy-review-2024-vol-12/340228.png","ImageObject",300,407,{"name":92,"@type":93},"River Wang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why has multiple myeloma immunotherapy been less promising compared with other cancers?","Question",{"text":112,"@type":113},"Recent checkpoint inhibitor strategies in MM have shown excessive side effects and/or low efficacy, particularly for advanced patients.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What role does the tumor microenvironment play in checkpoint inhibitor response in multiple myeloma?",{"text":117,"@type":113},"Exhaustion marker–related lymphocyte states in the MM tumor microenvironment are described as pivotal to disease context and therapy-relevant mechanisms.",{"name":119,"@type":110,"acceptedAnswer":120},"Which inhibitory checkpoint pathways and related agents are covered in this review?",{"text":121,"@type":113},"The review discusses inhibitory molecules including TIGIT, Tim-3, LAG-3, and V-domain Ig Suppressor of T-cell activation, and killer immunoglobulin-like receptors, along with bispecific T-cell antibodies.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},340228,1790517658,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","TherapeuTic advances in  \nvaccines and immunotherapy Review  \n\n| Multiple myeloma and the potential of new checkpoint inhibitors for immunotherapy\u003Cbr>Ali N. Kamali*, Haleh Hamedifar*, Michael Eisenhut and Jose M. Bautista\u003Cbr>Abstract: Multiple myeloma (MM), a cancer of the bone marrow, is categorized as the second most common hematological malignancy of adults in the Western world. Despite dramatic improvements in immunotherapies in the field of cancers, MM immunotherapy has not been promising until now. Recent clinical studies of immune checkpoint inhibitor therapy, either alone or in combination with anticancer drugs, showed excessive side effects or low efficacy, particularly in advanced MM patients. In this context, lymphocyte levels of exhaustion markers play a pivotal role in the MM tumor microenvironment (TME) . Hence in the present review, the mechanisms relevant to MM of five inhibitory molecules including T-cell immunoreceptor with Ig and ITIM domains (TIGIT), T-cell immunoglobulin, and mucin domain 3 (Tim-3), lymphocyte activation gene-3 (LAG-3), V-domain Ig Suppressor of T-cell activation and killer immunoglobulin-like receptors along with bispecific T-cell antibodies (BsAbs) will be discussed. Further, we summarized the underlying biology of these checkpoints in cancer and their rapidly emerging role in pathways in MM along with presenting recent clinical trials in context.\u003Cbr>Keywords: Multiple myeloma, Check point inhibitors, Immunotherapy |  | TherAdv Vaccines Immunother\u003Cbr>2024, Vol. 12: 1–14\u003Cbr>DOI: 10. 1177/ 25151355241288453 © The Author(s), 2024.\u003Cbr>Article reuse guidelines: [sagepub.com/journals](sagepub.com/journals)permissions\u003Cbr>Correspondence to:\u003Cbr>Ali N. Kamali\u003Cbr>CinnaGen Medical Biotechnology Research Center, Alborz University of Medical Sciences, Karaj, Iran\u003Cbr>CinnaGen Research and Production Co. , Alborz, Iran\u003Cbr>[kamalia@cinnagen.com](kamalia@cinnagen.com); [alin_kamali@yahoo.com](alin_kamali@yahoo.com)\u003Cbr>Haleh Hamedifar\u003Cbr>CinnaGen Medical Biotechnology Research Center, Alborz University of Medical Sciences, Karaj, Iran\u003Cbr>CinnaGen Research and Production Co. , Alborz, Iran\u003Cbr>Michael Eisenhut\u003Cbr>Department of Pediatrics, Luton & Dunstable University Hospital, Luton, UK\u003Cbr>Jose M. Bautista\u003Cbr>Department of Biochemistry and Molecular Biology, Complutense University of Madrid, Faculty of Veterinary Sciences, Madrid, Spain Research Institute Hospital 12 de Octubre, Madrid, Spain\u003Cbr>*These authors contributed equally to this work |\n| --- | --- | --- |\n| Introduction\u003Cbr>Cancer immunotherapy for the treatment of neoplastic disease has been consistently raising attention over the past century. Multiple myeloma (MM) is a cancer of clonal plasma cells that accounts for approximately 10% of hematological malignancy.1 In multiple myeloma, the bone marrow (BM) microenvironment, including the immune cell components, is pivotally involved in disease development and pathogenesis.2 In the BM microenvironment, the extensive interaction among bone marrow stromal cells (BMSCs), BM endothelial cells, and the MM cells may lead to secretion of various cytokines such as hepatocyte growth factor, transforming growth factor-β(TGF-β), vascular endothelial growth factor, and stromal cell-derived factor-1α (SDF-1α) that increase myeloma cells durability.3 The interaction between myeloma cells and BMSCs releases interleukine-6, which further enhances the durability of the malignant cells and, interestingly, the association between increased levels of IL-6 and IL-17A and survival has been recently reported in patients with newly | diagnosed multiple myeloma.4,5 Under optimal physiological circumstances, the immune system actively eliminates neoplastic cells persistently emerging.6 In this context, the tumorigenic antigens that are recognized by major histocompatibility complexes are introduced to antigenpresenting cells (APCs), including dendritic cells, macrophages, and B cells, that finally differentiate effector T cel","cbCaitUiUuRxf6eM","https://ap.wps.com/l/cbCaitUiUuRxf6eM","pdf",552325,14,"English","# Introduction\n## Immunotherapy and immune regulation in multiple myeloma","[{\"question\":\"Why has multiple myeloma immunotherapy been less promising compared with other cancers?\",\"answer\":\"Recent checkpoint inhibitor strategies in MM have shown excessive side effects and/or low efficacy, particularly for advanced patients.\"},{\"question\":\"What role does the tumor microenvironment play in checkpoint inhibitor response in multiple myeloma?\",\"answer\":\"Exhaustion marker–related lymphocyte states in the MM tumor microenvironment are described as pivotal to disease context and therapy-relevant mechanisms.\"},{\"question\":\"Which inhibitory checkpoint pathways and related agents are covered in this review?\",\"answer\":\"The review discusses inhibitory molecules including TIGIT, Tim-3, LAG-3, and V-domain Ig Suppressor of T-cell activation, and killer immunoglobulin-like receptors, along with bispecific T-cell antibodies.\"}]","TherapeuTic advances in vaccines and immunotherapy - Review - 2024 Vol. 12 | PDF",1790035058,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b9bb57849999d0a7b1e6f5e1698116a4.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a69cf5554ec796161dba4134aacf4195.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6817bf467211673be72a4e030f76a516.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5d118e4e7a7899a90c8786da7e8459c9.webp",980,1306]